Blueprint Medicines Corp (BPMC)
93.00
+2.27
(+2.50%)
USD |
NASDAQ |
Apr 26, 16:00
93.14
+0.14
(+0.16%)
After-Hours: 20:00
Blueprint Medicines Enterprise Value: 5.223B for April 26, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 26, 2024 | 5.223B |
| April 25, 2024 | 5.084B |
| April 24, 2024 | 5.177B |
| April 23, 2024 | 5.179B |
| April 22, 2024 | 5.076B |
| April 19, 2024 | 4.846B |
| April 18, 2024 | 4.972B |
| April 17, 2024 | 4.940B |
| April 16, 2024 | 4.800B |
| April 15, 2024 | 4.744B |
| April 12, 2024 | 4.871B |
| April 11, 2024 | 5.177B |
| April 10, 2024 | 5.069B |
| April 09, 2024 | 5.174B |
| April 08, 2024 | 5.133B |
| April 05, 2024 | 5.140B |
| April 04, 2024 | 5.081B |
| April 03, 2024 | 5.176B |
| April 02, 2024 | 5.135B |
| April 01, 2024 | 5.432B |
| March 28, 2024 | 5.337B |
| March 27, 2024 | 5.332B |
| March 26, 2024 | 5.019B |
| March 25, 2024 | 4.930B |
| March 22, 2024 | 4.858B |
| Date | Value |
|---|---|
| March 21, 2024 | 5.042B |
| March 20, 2024 | 4.933B |
| March 19, 2024 | 4.915B |
| March 18, 2024 | 4.844B |
| March 15, 2024 | 5.070B |
| March 14, 2024 | 4.899B |
| March 13, 2024 | 5.076B |
| March 12, 2024 | 5.021B |
| March 11, 2024 | 5.007B |
| March 08, 2024 | 5.180B |
| March 07, 2024 | 5.164B |
| March 06, 2024 | 5.062B |
| March 05, 2024 | 5.019B |
| March 04, 2024 | 5.088B |
| March 01, 2024 | 5.353B |
| February 29, 2024 | 5.255B |
| February 28, 2024 | 5.373B |
| February 27, 2024 | 5.639B |
| February 26, 2024 | 5.348B |
| February 23, 2024 | 5.008B |
| February 22, 2024 | 4.794B |
| February 21, 2024 | 4.871B |
| February 20, 2024 | 5.116B |
| February 16, 2024 | 5.055B |
| February 15, 2024 | 4.890B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.458B
Minimum
Nov 09 2022
6.180B
Maximum
Dec 23 2020
3.616B
Average
3.442B
Median
May 21 2019
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 16.63B |
| Apellis Pharmaceuticals Inc | 5.754B |
| Ionis Pharmaceuticals Inc | 5.013B |
| Madrigal Pharmaceuticals Inc | 3.328B |
| Sarepta Therapeutics Inc | 11.65B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -110.92M |
| Revenue (Quarterly) | 71.96M |
| Total Expenses (Quarterly) | 177.11M |
| EPS Diluted (Quarterly) | -1.82 |
| Gross Profit Margin (Quarterly) | 99.64% |
| Profit Margin (Quarterly) | -154.1% |
| Earnings Yield | -8.99% |
| Normalized Earnings Yield | -8.989 |